AIML Establishes Medical Advisory Board to Drive AI Powered ECG Signal Processing Innovation
AIML (AIMLF) has announced the formation of its Medical Advisory Board to guide the development and implementation of its AI-powered ECG signal-processing platforms 惭补虫驰颈别濒诲鈩� and 颁补谤诲颈辞驰颈别濒诲鈩�. The board comprises six distinguished cardiovascular experts from leading institutions, including the University of Toronto and University of British Columbia. Peter Kendall, AIML's President and Chief Commercialization Officer, will chair the board, leveraging his 20+ years of experience in health technology commercialization.
The advisory board will focus on steering clinical direction, trial design, and real-world deployment of AIML's flagship AI platforms. Simultaneously, the company has launched its redesigned corporate website, AIML.Health, serving as an interactive platform for stakeholders.
AIML (AIMLF) ha annunciato la creazione del suo Medical Advisory Board, incaricato di guidare lo sviluppo e l'implementazione delle sue piattaforme di elaborazione dei segnali ECG potenziate dall'IA, 惭补虫驰颈别濒诲鈩� e 颁补谤诲颈辞驰颈别濒诲鈩�. Il comitato 猫 composto da sei rinomati esperti cardiovascolari provenienti da istituzioni di primo piano, tra cui l'Universit脿 di Toronto e l'Universit脿 della British Columbia. Peter Kendall, Presidente e Chief Commercialization Officer di AIML, presieder脿 il board, mettendo a frutto oltre 20 anni di esperienza nella commercializzazione di tecnologie sanitarie.
Il comitato consultivo si concentrer脿 sull'orientamento clinico, la progettazione degli studi e l'implementazione reale delle piattaforme AI di punta di AIML. Parallelamente, l'azienda ha lanciato il suo sito web aziendale rinnovato, AIML.Health, che funger脿 da piattaforma interattiva per gli stakeholder.
AIML (AIMLF) ha anunciado la formaci贸n de su Medical Advisory Board para guiar el desarrollo e implementaci贸n de sus plataformas de procesamiento de se帽ales ECG impulsadas por IA, 惭补虫驰颈别濒诲鈩� y 颁补谤诲颈辞驰颈别濒诲鈩�. El consejo est谩 compuesto por seis destacados expertos cardiovasculares de instituciones l铆deres, incluyendo la Universidad de Toronto y la Universidad de British Columbia. Peter Kendall, presidente y director de comercializaci贸n de AIML, presidir谩 el consejo, aprovechando sus m谩s de 20 a帽os de experiencia en la comercializaci贸n de tecnolog铆a sanitaria.
El consejo asesor se enfocar谩 en dirigir la orientaci贸n cl铆nica, el dise帽o de ensayos y el despliegue en el mundo real de las plataformas de IA principales de AIML. Al mismo tiempo, la empresa ha lanzado su sitio web corporativo redise帽ado, AIML.Health, que servir谩 como plataforma interactiva para los interesados.
AIML (AIMLF)電� AI 旮半皹 鞁爠霃� 鞁犿樃 觳橂Μ 頂岆灚韽检澑 惭补虫驰颈别濒诲鈩�鞕赌 颁补谤诲颈辞驰颈别濒诲鈩�鞚� 臧滊皽 氚� 甑槃鞚� 歆�霃勴晿旮� 鞙勴暣 鞚橂 鞛愲 鞙勳洂須岆ゼ 甑劚頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞙勳洂須岆姅 韱犽韱� 雽�頃欔祼鞕赌 敫岆Μ韹办嫓旎熂牍勳晞 雽�頃欔祼毳� 韽暔頃� 欤检殧 旮瓣磤鞚� 鞁槇甏� 攵勳暭 鞝�氇呿暅 鞝勲臧� 6氇呾溂搿� 甑劚霅橃柎 鞛堨姷雼堧嫟. Peter Kendall AIML鞚� 靷灔 瓴� 斓滉碃 靸侅梾頇� 毂呾瀯鞛愱皜 鞙勳洂須岆ゼ 鞚措亴氅� 瓯搓皶 旮办垹 靸侅梾頇� 攵勳暭鞐愳劀 20雲� 鞚挫儊鞚� 瓴巾棙鞚� 頇滌毄頃� 鞓堨爼鞛呺媹雼�.
鞛愲 鞙勳洂須岆姅 AIML鞚� 雽�響� AI 頂岆灚韽检潣 鞛勳儊 氚╉枼 靹れ爼, 鞛勳儊 鞁滍棙 靹り硠 氚� 鞁れ牅 鞝侅毄鞐� 欷戩爯鞚� 霊� 瓴冹瀰雼堧嫟. 霃欖嫓鞐� 須岇偓電� 鞚错暣甏�瓿勳瀽毳� 鞙勴暅 靸來樃鞛戩毄 頂岆灚韽� 鞐暊鞚� 頃橂姅 靸堧…瓴� 霐旍瀽鞚鸽悳 旮办梾 鞗轨偓鞚错姼 AIML.Health毳� 於滌嫓頄堨姷雼堧嫟.
AIML (AIMLF) a annonc茅 la cr茅ation de son Medical Advisory Board charg茅 d鈥檕rienter le d茅veloppement et la mise en 艙uvre de ses plateformes de traitement des signaux ECG aliment茅es par l鈥橧A, 惭补虫驰颈别濒诲鈩� et 颁补谤诲颈辞驰颈别濒诲鈩�. Le conseil est compos茅 de six experts cardiovasculaires 茅minents issus d鈥檌nstitutions de premier plan, notamment l鈥橴niversit茅 de Toronto et l鈥橴niversit茅 de la Colombie-Britannique. Peter Kendall, pr茅sident et Chief Commercialization Officer d鈥橝IML, pr茅sidera le conseil en s鈥檃ppuyant sur plus de 20 ans d鈥檈xp茅rience dans la commercialisation de technologies de sant茅.
Le conseil consultatif se concentrera sur l鈥檕rientation clinique, la conception des essais et le d茅ploiement sur le terrain des plateformes IA phares d鈥橝IML. Parall猫lement, l鈥檈ntreprise a lanc茅 son site web corporate repens茅, AIML.Health, qui servira de plateforme interactive pour les parties prenantes.
AIML (AIMLF) hat die Gr眉ndung seines Medical Advisory Board bekannt gegeben, das die Entwicklung und Implementierung seiner KI-gest眉tzten EKG-Signalverarbeitungsplattformen 惭补虫驰颈别濒诲鈩� und 颁补谤诲颈辞驰颈别濒诲鈩� begleiten soll. Das Gremium besteht aus sechs renommierten Kardiologie-Experten f眉hrender Institutionen, darunter die Universit盲t Toronto und die Universit盲t British Columbia. Peter Kendall, Pr盲sident und Chief Commercialization Officer von AIML, wird den Vorstand leiten und dabei auf seine 眉ber 20-j盲hrige Erfahrung in der Vermarktung von Gesundheitstechnologien zur眉ckgreifen.
Das Beratungsgremium wird sich auf die klinische Ausrichtung, Studiendesign und den praktischen Einsatz der f眉hrenden KI-Plattformen von AIML konzentrieren. Gleichzeitig hat das Unternehmen seine neu gestaltete Unternehmenswebsite AIML.Health gestartet, die als interaktive Plattform f眉r Interessengruppen dient.
- Establishment of high-profile Medical Advisory Board with leading cardiovascular experts
- Strategic positioning to enhance clinical validation and regulatory pathways
- Strong leadership with experienced CCO as board chair
- None.
Medical Advisory Board will guide clinical studies, regulatory strategy, and global adoption of AIML's AI鈥慸riven ECG signal鈥憄rocessing solutions 惭补虫驰颈别濒诲鈩� and 颁补谤诲颈辞驰颈别濒诲鈩� across wearables and cardiology workflows.
AIML simultaneously debuts its redesigned corporate website, , offering an interactive hub for investors, partners, and stakeholders.
TORONTO, ON / / May 20, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQBAIMLF)(FWB:42FB) today announced the establishment of its Medical Advisory Board, composed of leading cardiovascular experts who will steer the clinical direction, trial design, and real鈥憌orld deployment of the Company's flagship AI platforms 惭补虫驰颈别濒诲鈩� and 颁补谤诲颈辞驰颈别濒诲鈩�.
Members of the inaugural Medical Advisory Board include:
顿谤.鈥疨补耻濒鈥疍辞谤颈补苍,鈥疢顿,鈥疢厂肠,鈥疐搁颁笔颁,鈥疐础颁颁鈥�- Professor of Medicine, University of Toronto; Staff Cardiologist, Division of Cardiology, St. Michael's Hospital
Dr.鈥疉lan鈥疪abinowitz,MBChB, FRCPC, FACC - Chief Medical Officer, AIML; Cardiologist and formerly Director of the Coronary Care Unit, St. Paul's Hospital Heart Centre/ Center for Heart Lung Innovation; Clinical Associate Professor, Division of Cardiology, University of British Columbia
Dr.鈥疊rett鈥疕eilbron,MBChB, FRCPC, FACC - Medical Director, Electrodiagnostics Program; Clinical Associate Professor, Division of Cardiology, University of British Columbia; St. Paul's Hospital Heart Centre, Vancouver, BC
Dr.鈥疢arc鈥疍eyell,MD MSc FHRS FCCS - Clinical Professor, University of British Columbia; Director, Heart Rhythm Services, St. Paul's Hospital
顿谤.鈥疭补耻濒鈥疘蝉蝉别谤辞飞,鈥疢叠叠颁丑,鈥疐搁颁笔(颁),鈥疐础颁颁鈥�- Director, Cardiology, UBC Hospital; Director, Sports Cardiology BC
顿谤.鈥疜颈尘鈥疌辞苍苍别濒濒测,鈥疢叠叠厂,鈥疨丑顿,鈥疐搁础颁笔,鈥疐搁颁笔颁鈥�- Professor of Medicine and Physiology, University of Toronto; Cardiologist and Scientist, St. Michael's Hospital
笔别迟别谤鈥疜别苍诲补濒濒, President and Chief Commercialization Officer, will serve as Chair of the Medical Advisory Board, ensuring a strong bridge between clinical insight and AIML's commercialization strategy. With more than two decades of experience leading go-to-market programs for breakthrough health technologies, Peter is uniquely positioned to translate scientific and clinical guidance into scalable solutions. Under his leadership, the Board's recommendations will be integrated into AIML's core operations-ensuring that clinical guidance translates directly into product development, regulatory strategy, and commercial execution.
Paul鈥疍uffy, Executive鈥疌hairman and CEO of AIML comments. "The launch of our Medical Advisory Board reinforces AIML's commitment to marrying world鈥慶lass science with advanced AI. Together, we will set new standards for AI鈥慹nhanced cardiac diagnostics."
笔别迟别谤鈥疜别苍诲补濒濒 - Chair, Medical Advisory Board; President & CCO, AIML says "Uniting this calibre of clinical expertise ensures our product roadmap remains grounded in frontline insight. Their guidance will be invaluable as we expand licensing and regulatory pathways."
AIML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health.
For more information about AIML:
For detailed information please see AIML's website or the Company's filed documents at.
Contact:
Blake Fallis
(778) 405-0882
[email protected]
About AIML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
With a growing portfolio of regulatory filings, including a 510(k) premarket notification and a registered FDA Device Master File, AIML is committed to rigorous validation and broad interoperability.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services as currently proposed or at all. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations, Inc.
View the original on ACCESS Newswire
FAQ
Who are the key members of AIML's new Medical Advisory Board?
What is the purpose of AIMLF's Medical Advisory Board?
Who is chairing AIML's Medical Advisory Board?
What products will AIMLF's Medical Advisory Board focus on?
